TY - JOUR
T1 - SARS-CoV-2 Antibody Seroprevalence in Jakarta, Indonesia
AU - Ariawan, Iwan
AU - Jusril, Hafizah
AU - Farid, Muhammad N.
AU - Riono, Pandu
AU - Wahyuningsih, Wiji
AU - Widyastuti,
AU - Handayani, Dwi Oktavia T.L.
AU - Wahyuningsih, Endang Sri
AU - Daulay, Rebekka
AU - Henderiawati, Retno
AU - Malik, Safarina G.
AU - Noviyanti, Rintis
AU - Trianty, Leily
AU - Fadila, Nadia
AU - Myint, Khin Saw Aye
AU - Yudhaputri, Frilasita A.
AU - Venkateswaran, Neeraja
AU - Venkateswaran, Kodumudi
AU - Udhayakumar, Venkatachalam
AU - Hawley, William A.
AU - Morgan, Juliette
AU - Pronyk, Paul M.
N1 - Funding Information:
The authors acknowledge all health facility staff in the Special Capital Region of Jakarta, Indonesia, who led and collected these important data. The authors also would like to thank the Civil Registry Office, heads of urban villages, and heads of neighborhoods in the Special Capital Region of Jakarta for supporting the data collection schedules and venues. The authors would like to thank Agatha Mia Puspitasari, Ristya Amalia, Hidar, and Fahira Ainun Nisa from the Eijkman Institute for Molecular Biology for their support in running the Luminex assays.
Publisher Copyright:
Copyright © 2022, Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)
PY - 2022/8
Y1 - 2022/8
N2 - The SARS-CoV-2 transmission dynamics in low- and middle-income countries remain poorly understood. This study aimed to estimate the SARS-CoV-2 antibodies seroprevalence in Jakarta, Indonesia, and to increase knowledge of SARS-CoV-2 transmission in urban settings. A population-based serosurvey among individuals aged one year or older was conducted in Jakarta. Employing a multistage sampling design, samples were stratified by district, slum and non-slum residency, sex, and age group. Blood samples were tested for IgG against three different SARS-CoV-2 antigens. Seroprevalence was estimated after applying sample weights and adjusting for cluster characteristics. In March 2021, this study collected 4,919 respondents. The weighted estimate of seroprevalence was 44.5% (95% CI = 42.5-46.5). Seroprevalence was highest among adults aged 30-49 years, with higher seroprevalence in women and the overweight/obese group. Respondents residing in slum areas were 1.3-fold more likely to be seropositive than non-slum residents. It was estimated that 4,717,000 of Jakarta's 10.6 million residents had prior SARS-CoV-2 infection. This suggests that approximately 10 infections were undiagnosed/underreported for every reported case. About one year after the first COVID-19 case was confirmed, close to half of Jakarta's residents have been infected by SARS-CoV-2.
AB - The SARS-CoV-2 transmission dynamics in low- and middle-income countries remain poorly understood. This study aimed to estimate the SARS-CoV-2 antibodies seroprevalence in Jakarta, Indonesia, and to increase knowledge of SARS-CoV-2 transmission in urban settings. A population-based serosurvey among individuals aged one year or older was conducted in Jakarta. Employing a multistage sampling design, samples were stratified by district, slum and non-slum residency, sex, and age group. Blood samples were tested for IgG against three different SARS-CoV-2 antigens. Seroprevalence was estimated after applying sample weights and adjusting for cluster characteristics. In March 2021, this study collected 4,919 respondents. The weighted estimate of seroprevalence was 44.5% (95% CI = 42.5-46.5). Seroprevalence was highest among adults aged 30-49 years, with higher seroprevalence in women and the overweight/obese group. Respondents residing in slum areas were 1.3-fold more likely to be seropositive than non-slum residents. It was estimated that 4,717,000 of Jakarta's 10.6 million residents had prior SARS-CoV-2 infection. This suggests that approximately 10 infections were undiagnosed/underreported for every reported case. About one year after the first COVID-19 case was confirmed, close to half of Jakarta's residents have been infected by SARS-CoV-2.
KW - antibodies
KW - COVID-19
KW - immunity
KW - SARS-CoV-2
KW - seroprevalence
UR - http://www.scopus.com/inward/record.url?scp=85140779977&partnerID=8YFLogxK
U2 - 10.21109/kesmas.v17i3.6070
DO - 10.21109/kesmas.v17i3.6070
M3 - Article
AN - SCOPUS:85140779977
SN - 1907-7505
VL - 17
SP - 169
EP - 174
JO - Kesmas
JF - Kesmas
IS - 3
ER -
